Targeted treatment of psoriasis with adalimumab: A critical appraisal based on a systematic review of the literature

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 303-318

  Schmitt, Jochen ^a   Wozel, Gottfried ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Adalimumab; Biologic; Effectiveness; Efficacy; Efficiency; Psoriasis; Safety; Treatment

Indexed keywords

EID: 77951518489     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S3081     Document Type: Review

References (113)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263-271.
2. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:121-128.
3. de Korte J, Sprangers MA, Mombers FM, et al. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9:140-147.
4. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19:225-230.
5. Kremers HM, McEvoy MT, Dann FJ, et al. Heart disease in psoriasis. J Am Acad Dermatol. 2007;57:347-354.
6. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493-1499.
7. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-1741.
8. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology. 2007;215:17-27.
9. Gupta MA, Schork NJ, Gupta AK, et al. Suicidal ideation in psoriasis. Int J Dermatol. 1993;32:188-190.
10. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-139.
11. Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46:850-860.
12. Schmitt J, Ford DE. Work Limitations and Productivity Loss are Associated with Health-related Quality of Life but not with Clinical Severity in Patients with Psoriasis. Dermatology. 2006;213:110.
13. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272-284.
14. Nast A, Kopp IB, Augustin M, et al. [S3-Guidelines for the therapy of psoriasis vulgaris]. J Dtsch Dermatol Ges. 2006;4 Suppl 2:S1-126.
15. British Association of Dermatologists. Psoriasis Guideline 2006. Available at http://www.library.nhs.uk/guidelinesfinder/ViewResource. aspx?resIDa125323. 2006. British Association of Dermatologists. 3131-2008.
16. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins, 1986. J Immunol. 2005;175:5-14.
17. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med. 2007;13:242-244.
18. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-1684.
19. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-1674.
20. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144:200-207.
21. EMEA. European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab). 19 Feb 2009. London, UK, EMEA.
22. Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology of tumor necrosis factor-alpha-implications for psoriasis. Exp Dermatol. 2004;13:193-222.
23. Wakefield PE, James WD, Samlaska CP, et al. Tumor necrosis factor. J Am Acad Dermatol. 1991;24:675-685.
24. Davenport CM, McAdams HA, Kou J, et al. Inhibition of pro-inflammatory cytokine generation by CTLA4-Ig in the skin and colon of mice adoptively transplanted with CD45RBhi CD4ttT cells correlates with suppression of psoriasis and colitis. Int Immunopharmacol. 2002;2:653-672.
25. Nickoloff BJ, Karabin GD, Barker JN, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol. 1991;138:129-140.
26. Kristensen M, Chu CQ, Eedy DJ, et al. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol. 1993;94:354-362.
27. Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994;96:146-151.
28. Bonifati C, Carducci M, Cordiali FP, et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients-relationships with disease severity. Clin Exp Dermatol. 1994;19:383-387.
29. Mussi A, Bonifati C, Carducci M, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents. 1997;11:115-118.
30. Uyemura K, Yamamura M, Fivenson DF, et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101:701-705.
31. Partsch G, Wagner E, Leeb BF, et al. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol. 1998;25:105-110.
32. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998;25:1544-1552.
33. Hohler T, Kruger A, Schneider PM, et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol. 1997;109:562-565.
34. Beyaert R, De Potter C, Vanhaesebroeck B, et al. Induction of inflammatory cell infiltration and necrosis in normal mouse skin by the combined treatment of tumor necrosis factor and lithium chloride. Am J Pathol. 1991;138:727-739.
35. Palladino MA, Bahjat FR, Theodorakis EA, et al. Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov. 2003;2:736-746.
36. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244-279.
37. Sabat R, Philipp S, Hoflich C, et al. Immunopathogenesis of psoriasis. Exp Dermatol. 2007;16:779-798.
38. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol. 2006;33:1447-1451.
39. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis. 1999;58 Suppl 1:I70-I72.
40. EMEA. SCIENTIFIC DISCUSSION, Humira (Adalimumab). Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/ humira/400803en6.pdf, accessed March 24, 2009. 2004.
41. FDA. Package insert Humira (adalimumab), U.S. Govt. Lic. No. 0043, Abbott Laboratories. Available at http://www.fda.gov/Cder/foi/ label/2002/adalabb123102LB.htm, accessed March 24, 2009. 2002.
42. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25:1700-1721.
43. DeRuiter J, Riley TN. How can adalimumab (Humira) be used to treat rheumatoid arthritis? US Pharmacist. [serial online] 2003;28(5).
44. Santora LC, Kaymakcalan Z, Sakorafas P, et al. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem. 2001;299:119-129.
45. Tjioe M, Gerritsen MJ, Den Broeder AA, et al. Adalimumab, a fully human anti-TNF-alpha monoclonal antibody, treatment does not influence experimental UV response in the skin of rheumatoid arthritis patients. Exp Dermatol. 2003;12:460-465.
46. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157:238-244.
47. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-735.
48. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598-606.
49. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115.
50. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558-566.
51. Revicki DA, Menter A, Feldman S, et al. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008;6:75.
52. Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008;158:549-557.
53. Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18:341-350.
54. Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007;18:25-31.
55. Nijsten T, Spuls PI. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis. Br J Dermatol. 2008;159:257-258.
56. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for longterm treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476-488.
57. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279-3289.
58. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;69:702-709.
59. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34:1040-1050.
60. Revicki DA, Willian MK, Menter A, et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216:260-270.
61. Gladman DD, Mease PJ, Cifaldi MA, et al. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis. 2007;66: 163-168.
62. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007;57: 269-275.
63. Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234-240.
64. Van L, Modi SV, Yang DJ, et al. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment. Arch Dermatol. 2008;144:804-806.
65. Seitz M, Wirthmuller U, Moller B, et al. The-308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007;46:93-96.
66. Tutuncu Z, Kavanaugh A, Zvaifler N, et al. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 2005;52:2693-2696.
67. Nelson AA, Pearce DJ, Fleischer AB, Jr, et al. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58:125-135.
68. Sizto S, Bansback N, Feldman SR, et al. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2008; Dec 13 [Epub ahead of print].
69. Goldberg LD. The convergence of psoriasis treatment cost-effectiveness over time: "real world" considerations in economic modeling. J Am Acad Dermatol. 2008;58:1073-1075.
70. Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford). 2007;46:695-698.
71. Berthelot CN, George SJ, Hsu S. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol. 2005;53:S260-S262.
72. Chung JH, Van Stavern GP, Frohman LP, et al. Adalimumab-associated optic neuritis. J Neurol Sci. 2006;244:133-136.
73. Fulchiero GJ Jr, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol. 2007;56:S65-S67.
74. George SJ, Anderson HL, Hsu S. Adalimumab-induced urticaria. Dermatol Online J. 2006;12:4.
75. Smith DI, Heffernan MP. Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol. 2008;58:S50-S52.
76. Wu JJ, Tsai TF. Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis. Arch Dermatol. 2008;144:1403-1404.
77. Sheth N, Greenblatt D, Patel S, et al. Adalimumab-induced cutaneous lupus. Clin Exp Dermatol. 2007;32:593-594.
78. Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol. 2006;142:198-202.
79. Tubach F, Ravaud P, Salmon-Ceron D, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis. 2006;43:e95-e100.
80. Dalmau J, Roe E, Corella F, et al. Acute generalized skin eruption due to adalimumab: report of two cases. J Eur Acad Dermatol Venereol. 2007;21:1105-1106.
81. Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1-14.
82. Papadavid E, Gazi S, Dalamaga M, et al. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management. J Eur Acad Dermatol Venereol. 2008;22:380-382.
83. Zangrilli A, Papoutsaki M, Talamonti M, et al. Long-term efficacy of adalimumab in generalized pustular psoriasis. J Dermatolog Treat. 2008;19:185-187.
84. Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatolog Treat. 2005;16:350-352.
85. Stinco G, Piccirillo F, Patrone P. Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. Br J Dermatol. 2007;157:1273-1274.
86. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
87. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-263.
88. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-216.
89. Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res. 1993;2:169-180.
90. Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004;17:427-431.
91. Mossner R, Schon MP, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol. 2008;26:486-502.
92. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med. 2006;174:736-742.
93. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest. 2007;131:1898-1906.
94. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59:209-217.
95. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation. 1996;61:715-721.
96. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177-186.
97. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681-1691.
98. Saladi RN, Persaud AN. The causes of skin cancer: a comprehensive review. Drugs Today (Barc). 2005;41:37-53.
99. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358:1042-1045.
100. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862-2869.
101. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999;53:457-465.
102. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996-1001.
103. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156:486-491.
104. Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf. 2005;4:637-641.
105. Kirshen C, Kanigsberg N. Alopecia areata following adalimumab. J Cutan Med Surg. 2009;13:48-50.
106. Garcia BN, Lee HH, Worm M, et al. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol. 2006;142:1654-1655.
107. Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21:3365-3369.
108. Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008;67:710-712.
109. Aslanidis S, Vassiliadis T, Pyrpasopoulou A, et al. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol. 2007;26:261-264.
110. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159:513-526.
111. Rich SJ. Considerations for assessing the cost of biologic agents in the treatment of psoriasis. J Manag Care Pharm. 2004;10:S38-S41.
112. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005;24:52-57.
113. Burmester GR, Mease PJ, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009; Jan 15 [Epub ahead of print].